Video

Dr. Eng on the Potential of Trastuzumab Deruxtecan in HER2+ mCRC

Author(s):

Cathy Eng, MD, FACP, FASCO, discusses the potential of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic colorectal cancer.

Cathy Eng, MD, FACP, FASCO, David H. Johnson Chair in Surgical and Medical Oncology; co-leader of the Gastrointestinal (GI) Cancer Research Program; professor of medicine in hematology and oncology; co-director of GI Oncology; vice chair of the SWOG GI Committee; and director of the VICC Young Adult Cancers Initiative at Vanderbilt-Ingram Cancer Center, discusses the potential of fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with HER2-positive metastatic colorectal cancer (mCRC).

Trastuzumab deruxtecan is one particular agent of interest in mCRC, having been evaluated in patients who had previously received a HER2-targeted therapy, according to Eng. Although HER2 positivity is rare in CRC, occurring in only 5% of patients, trastuzumab (Herceptin) has previously demonstrated benefit in this population; however, these patients may experience disease progression on the agent, Eng notes. As such, trastuzumab deruxtecan is being evaluated in the phase 2 DESTINY-CRC01 trial (NCT03384940) in patients who had previously received trastuzumab, Eng explains.

In December 2019, trastuzumab deruxtecan received FDA approval for use in patients with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti–HER2-based regimens in the metastatic setting. More recently, in January 2021, the antibody-drug conjugate received regulatory approval for use in patients with locally advanced or metastatic HER2-positive gastric gastroesophageal junction adenocarcinoma who have previously received a trastuzumab-based regimen.

Related Videos
Aparna Parikh, MD
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Aparna Parikh, MD, associate professor, medicine, Harvard Medical School; assistant in medicine, Hematology, Oncology, Massachusetts General Hospital; attending oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, the Henri and Belinda Termeer Center for Targeted Therapies
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.